At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 566 enrolled
Drug / intervention
Brolucizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Two-year, Three-arm, Randomized, Double-masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic Macular Edema
In Brief
A Phase 3 clinical trial evaluating Brolucizumab and Aflibercept for Diabetic Macular Edema. Completed, enrolled 566 participants across 116 sites in 14 countries.
Detailed Summary
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with visual impairment due to diabetic macular edema (DME).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Macular Edema
CountriesArgentina, Australia, Austria, Canada, Colombia, Israel, Italy, Japan, Netherlands, Portugal, Puerto Rico, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedMar 2018
Enrollment StartJul 2018
Primary CompletionNov 2020
Study CompletionOct 2021
TodayJul 2026
First PostedMar 29, 2018
Enrollment StartJul 23, 2018
Primary CompletionNov 11, 2020
Study CompletionOct 18, 2021
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 8.3 years ago
Interventions
Brolucizumabdrug
Intravitreal injection
Afliberceptdrug
Intravitreal injection